Benjamin Comer bio
Ben Comer is senior editor at Pharmaceutical Executive. Prior to joining PE, he worked as a reporter for several years at Haymarket Media's Medical Marketing & Media magazine, covering professional and consumer pharmaceutical marketing strategy and tactics, traditional and digital media, and U.S. regulatory policy. Ben is a licensed but no-longer-practicing pharmaceutical technician, and a voracious reader. In 2005, he received an undergraduate degree in journalism and media studies from the College of Charleston, South Carolina, and taught an English language class in Zhuji, China, in 2004, though he unfortunately speaks very little Mandarin. Ben’s reportage at Medical Marketing & Media (MM&M) has been published variously in aggregate online, and his work has also appeared in PR Week and Direct Marketing News, sister titles to MM&M, and most recently the Green Hills News, a local newspaper in Nashville, Tennessee. Aside from journalistic endeavors, Ben has worked as a boom operator on independent films in the New York City area, a bike courier (very briefly), a screenwriter (unpaid), and an unpublished fiction writer.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.